William Blair & Company
BEAM icon

William Blair & Company’s Beam Therapeutics BEAM Stock Holding History

William Blair & Company’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,292
Closed -$252K – 1821
2022
Q3 		$252K Sell
5,292
-1,000
-16% -$57K ﹤0.01% 1301
2022
Q2 		$244K Hold
6,292
– – ﹤0.01% 1344
2022
Q1 		$361K Buy
6,292
+1,800
+40% +$118K ﹤0.01% 1288
2021
Q4 		$358K Buy
4,492
+742
+20% +$63.5K ﹤0.01% 1351
2021
Q3 		$326K Buy
3,750
+450
+14% +$45.2K ﹤0.01% 1312
2021
Q2 		$425K Hold
3,300
– – ﹤0.01% 1207
2021
Q1 		$264K Sell
3,300
-450
-12% -$42.8K ﹤0.01% 1380
2020
Q4 		$306K Buy
+3,750
New +$184K ﹤0.01% 1256

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

William Blair & Company's BEAM Position: Q4 2022 in Review

William Blair & Company sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 5,292 shares — an estimated $252K sold.

William Blair & Company first reported a position in BEAM in Q4 2020 and held it in 8 quarters. The position peaked at $425K in Q2 2021. 207 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

  • William Blair & Company reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
  • William Blair & Company sold 5,292 Beam Therapeutics shares in Q4 2022, an estimated $252K.
  • William Blair & Company first reported a position in Beam Therapeutics in Q4 2020 and held it in 8 quarters.
  • William Blair & Company's Beam Therapeutics position peaked at $425K in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on William Blair & Company's 13F filing for Q4 2022, filed 10 Feb 2023.